The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

  • Stephen A. Klassen
  • , Jonathon W. Senefeld
  • , Patrick W. Johnson
  • , Rickey E. Carter
  • , Chad C. Wiggins
  • , Shmuel Shoham
  • , Brenda J. Grossman
  • , Jeffrey P. Henderson
  • , James Musser
  • , Eric Salazar
  • , William R. Hartman
  • , Nicole M. Bouvier
  • , Sean T.H. Liu
  • , Liise anne Pirofski
  • , Sarah E. Baker
  • , Noud van Helmond
  • , R. Scott Wright
  • , De Lisa Fairweather
  • , Katelyn A. Bruno
  • , Zhen Wang
  • Nigel S. Paneth, Arturo Casadevall, Michael J. Joyner

Research output: Contribution to journalReview articlepeer-review

120 Scopus citations

Abstract

To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-response studies, and 96 case reports or case series. Studies published between January 1, 2020, and January 16, 2021, were identified through a systematic search of online PubMed and MEDLINE databases. Random effects analyses of randomized clinical trials and matched control data demonstrated that patients with COVID-19 transfused with convalescent plasma exhibited a lower mortality rate compared with patients receiving standard treatments. Additional analyses showed that early transfusion (within 3 days of hospital admission) of higher titer plasma is associated with lower patient mortality. These data provide evidence favoring the efficacy of human convalescent plasma as a therapeutic agent in hospitalized patients with COVID-19.

Original languageEnglish
Pages (from-to)1262-1275
Number of pages14
JournalMayo Clinic Proceedings
Volume96
Issue number5
DOIs
StatePublished - May 2021

Fingerprint

Dive into the research topics of 'The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis'. Together they form a unique fingerprint.

Cite this